Business Wire

CA-ENERGOUS

26.2.2020 22:04:06 CET | Business Wire | Press release

Share
Energous Secures Industry-first Regulatory Approval for its Revolutionary WattUp Wireless Charging Technology in Japan

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp®, a revolutionary wireless charging 2.0 technology, announced that it has received regulatory approval for its WattUp Near Field wireless charging technology in Japan.

“Having secured regulatory approval for our WattUp wireless charging technology in Japan is a major regulatory milestone for Energous,” said Stephen R. Rizzone, president and CEO of Energous Corporation. “This opens the door to sell WattUp-enabled products in a major Asia Pacific market.”

Energous’ WattUp wireless charging technology underwent testing by independent, accredited test labs and was determined to be compliant with all regulatory requirements in Japan.

“WattUp approval in Japan is a big step forward for Energous and our customers, while increasing momentum to achieve global market access,” said Dan Lawless, vice president of regulatory affairs at Energous Corporation. “We are establishing a regulatory framework for the large-scale deployment of wireless charging 2.0 through our substantial engagements in major international spectrum and standards organizations, combined with our direct work with governments around the world.”

“Currently wireless charging technologies – specifically non coil-based charging solutions – have not yet penetrated the Japan market, largely because Japan has historically proven to have a more rigid regulatory approval process. Energous Corporation is paving the way for the industry in the Japan market with the industry-first approval of its WattUp wireless charging technology. With this breakthrough, Energous continues to show progress in advancing its WattUp technology to meet the needs of partner and customer companies,” said Dinesh Kithany, lead industry analyst, wireless power and power supply at Omdia.

Some of the benefits of Energous’ WattUp technology for manufacturers include:

  • A small footprint allowing WattUp to be integrated into products of various form factors, including small devices with curved edges or without flat surfaces
  • Orientation freedom and 90-degree angle support
  • Foreign object detection eliminating thermal issues with metal and other materials
  • Interoperability with all WattUp-enabled products, even those from different manufacturers

To-date, Energous has secured regulatory approval for its WattUp wireless charging technology in the following countries:

Afghanistan

Bermuda

Curacao

Germany

Kosovo

Netherlands

Suriname

Albania

Bolivia

Cyprus

Ghana

Latvia

New Zealand

Sweden

Andorra

Bosnia and Herzegovina

Czech Republic

Greece

Liechtenstein

Nicaragua

Switzerland

Angola

Botswana

Denmark

Grenada

Lithuania

Norway

Taiwan

Antigua and Barbuda

Brazil

Djibouti

Guatemala

Luxembourg

Panama

Tajikistan

Argentina

Brunei

Dominican Republic

Guyana

Macedonia

Peru

Tanzania

Armenia

Bulgaria

Dominica

Honduras

Malawi

Philippines

Thailand

Aruba

Burkina Faso

Ecuador

Hungary

Maldives

Poland

Trinidad and Tobago

Australia

Cambodia

Egypt

Iceland

Malta

Portugal

Turkey

Austria

Canada

El Salvador

India

Mexico

Romania

United Arab Emirates

Azerbaijan

Cayman Island

Eritrea

Indonesia

Monaco

Serbia

Uganda

Bahamas

Central African Republic

Estonia

Ireland

Mongolia

Slovenia

The United Kingdom

Barbados

Chile

Ethiopia

Italy

Montenegro

Solomon Island

The United States

Belarus

Colombia

Finland

Jamaica

Mozambique

Slovakia

Uruguay

Belgium

Costa Rica

France

Japan

Myanmar (formerly Burma)

South Africa

Uzbekistan

Belize

Croatia

Georgia

Jordan

Nepal

Spain

Venezuela

Energous anticipates it will receive regulatory approval in additional markets later this year.

To learn more about Energous, please visit Energous.com or follow the company on Twitter , Facebook and LinkedIn .

About Energous Corporation

Energous Corporation (Nasdaq: WATT) is leading the next generation of wireless charging – wireless charging 2.0 – with its award-winning WattUp® technology, which supports fast, efficient contact-based charging, as well as charging at a distance. WattUp is a scalable, RF-based wireless charging technology that offers substantial improvements in contact-based charging efficiency, foreign object detection, orientation freedom and thermal performance compared to older, coil-based charging technologies. The technology can be designed into many different sized electronic devices for the home and office, as well as the medical, industrial, retail and automotive industries, and it ensures interoperability across products. Energous develops silicon-based wireless power transfer (WPT) technologies and customizable reference designs. These include innovative silicon chips, antennas and software, for a large variety of applications, such as smartphones, fitness trackers, hearables, medical sensors and more. Energous received the world’s first FCC Part 18 certification for at-a-distance wireless charging, and the company has 220 awarded patents for its WattUp wireless charging technology to-date. For more information, please visit Energous.com .

Safe Harbor Statement

This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include our statements about technology developments, partner product development and wireless charging innovation. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye